IL6 and hemophagocytic syndrome: Future research into targeted therapies, such as IL-1 or IL-6 inhibitors, and standardized protocols for adult HLH is warranted to address diagnostic delays and therapeutic limitations, ultimately reducing the devastating impact of this condition.